×
About 497,978 results
Intrauterine Device Expulsion After Postpartum Placement: A Systematic Review and Meta-... Preview
https://doi.org/10.1097/AOG.0000000000002822
Obstetrics and Gynecology; Jatlaoui TC, Whiteman MK et. al.

Sep 11th, 2018 - To estimate expulsion rates among women with postpartum intrauterine device (IUD) placement by timing of insertion, IUD type, and delivery method. We searched PubMed, Cochrane Library, and ClinicalTrials.gov from 1974 to May 2018. We searched databases for any published studies that examined postpartum placement of a copper IUD or levonorgestrel intrauterine system and reported counts of expuls...

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomi... Preview
https://doi.org/10.1016/S0140-6736(18)31551-4
Lancet (London, England); Meltzer-Brody S, Colquhoun H et. al.

Sep 4th, 2018 - Post-partum depression is associated with substantial morbidity, and improved pharmacological treatment options are urgently needed. We assessed brexanolone injection (formerly SAGE-547 injection), a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, for the treatment of moderate to severe post-partum depression. We did two double-blind, randomised, placebo-controlle...

Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Po... Preview
https://doi.org/10.1200/JCO.2018.79.2697
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Giordano SH, Temin S et. al.

Jun 25th, 2018 - Purpose To update evidence-based guideline recommendations for practicing oncologists and others on systemic therapy for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest ...

ACOG Committee Opinion No. 742: Postpartum Pain Management. Preview
https://doi.org/10.1097/AOG.0000000000002683
Obstetrics and Gynecology;

May 21st, 2018 - Pain and fatigue are the most common problems reported by women in the early postpartum period. Pain can interfere with a woman's ability to care for herself and her infant. Untreated pain is associated with a risk of greater opioid use, postpartum depression, and development of persistent pain. Nonpharmacologic and pharmacologic therapies are important components of postpartum pain management....

A Silent Epidemic: The Prevalence, Incidence and Persistence of Mycoplasma genitalium A... Preview
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005142
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Seña AC, Lee JY et. al.

Jan 17th, 2018 - Mycoplasma genitalium can result in pelvic inflammatory disease and adverse pregnancy outcomes. We analyzed data collected from a prospective study of asymptomatic bacterial vaginosis (BV) to determine the natural history of M. genitalium. Women aged 15-25 years, with asymptomatic BV and ≥2 risk factors for sexually transmitted infection were recruited from 10 sites throughout the United States...

IVF Transfer of Fresh or Frozen Embryos in Women without Polycystic Ovaries. Preview
https://doi.org/10.1056/NEJMoa1703768
The New England Journal of Medicine; Vuong LN, Dang VQ et. al.

Jan 10th, 2018 - Among women who are undergoing in vitro fertilization (IVF), the transfer of frozen embryos has been shown to result in a higher rate of live birth than the transfer of fresh embryos in those with infertility associated with the polycystic ovary syndrome. It is not known whether frozen-embryo transfer results in similar benefit in women with infertility that is not associated with the polycysti...

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy ... Preview
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838571
JAMA Psychiatry; Daly EJ, Singh JB et. al.

Dec 28th, 2017 - Approximately one-third of patients with major depressive disorder (MDD) do not respond to available antidepressants. To assess the efficacy, safety, and dose-response of intranasal esketamine hydrochloride in patients with treatment-resistant depression (TRD). This phase 2, double-blind, doubly randomized, delayed-start, placebo-controlled study was conducted in multiple outpatient referral ce...

Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Comm... Preview
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5820727
JAMA Zhao JG, Zeng XT et. al.

Dec 27th, 2017 - The increased social and economic burdens for osteoporosis-related fractures worldwide make the prevention of such injuries a major public health goal. Previous studies have reached mixed conclusions regarding the association between calcium, vitamin D, or combined calcium and vitamin D supplements and fracture incidence in older adults. To investigate whether calcium, vitamin D, or combined ca...

Contemporary Hormonal Contraception and the Risk of Breast Cancer. Preview
https://doi.org/10.1056/NEJMoa1700732
The New England Journal of Medicine; Mørch LS, Skovlund CW et. al.

Dec 6th, 2017 - Little is known about whether contemporary hormonal contraception is associated with an increased risk of breast cancer. We assessed associations between the use of hormonal contraception and the risk of invasive breast cancer in a nationwide prospective cohort study involving all women in Denmark between 15 and 49 years of age who had not had cancer or venous thromboembolism and who had not re...

Intrauterine insemination with ovarian stimulation versus expectant management for unex... Preview
https://doi.org/10.1016/S0140-6736(17)32406-6
Lancet (London, England); Farquhar CM, Liu E et. al.

Nov 27th, 2017 - Women with unexplained infertility are often offered intrauterine insemination (IUI) with ovarian stimulation as an alternative to in-vitro fertilisation (IVF). However, little evidence exists that IUI is an effective treatment. In 2013, the UK National Institute for Health and Care Excellence recommended that IUI should not be routinely offered for couples with unexplained infertility. For thi...

Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Place... Preview
https://doi.org/10.1176/appi.ajp.2017.16101200
The American Journal of Psychiatry; Sit DK, McGowan J et. al.

Oct 3rd, 2017 - Patients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited treatment options. Building on promising pilot data, the authors conducted a 6-week randomized double-blind placebo-controlled trial to investigate the efficacy of adjunctive bright light therapy at midday for bipolar depression. The aims were to determine remission rate, depression symptom level...

History of breast feeding and risk of incident endometriosis: prospective cohort study. Preview
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574033
BMJ (Clinical Research Ed.); Farland LV, Eliassen AH et. al.

Aug 30th, 2017 - Objective To investigate the association between lifetime breast feeding, exclusive breast feeding, postpartum amenorrhea, and incidence of endometriosis among parous women.Design Prospective cohort study.Setting Nurses' Health Study II, 1989-2011.Participants 72 394women who reported having one or more pregnancies that lasted at least six months, 3296 of whom had laparoscopically confirmed end...

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. Preview
https://doi.org/10.1056/NEJMoa1706450
The New England Journal of Medicine; Robson M, Im SA et. al.

Jun 5th, 2017 - Olaparib is an oral poly(adenosine diphosphate-ribose) polymerase inhibitor that has promising antitumor activity in patients with metastatic breast cancer and a germline BRCA mutation. We conducted a randomized, open-label, phase 3 trial in which olaparib monotherapy was compared with standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor type 2 (...

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. Preview
https://doi.org/10.1056/NEJMoa1612645
The New England Journal of Medicine; Masuda N, Lee SJ et. al.

May 31st, 2017 - Patients who have residual invasive carcinoma after the receipt of neoadjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-negative breast cancer have poor prognoses. The benefit of adjuvant chemotherapy in these patients remains unclear. We randomly assigned 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy (containing anthracyc...

Association of Primary Care Clinic Appointment Time With Clinician Ordering and Patient Completion of Breast and Colorectal Cancer Screening
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2733171
JAMA Network Open; Hsiang, E. et. al.

May 9th, 2019 - Question Are breast and colorectal cancer screening rates associated with the time of day a patient visits the primary care clinician? Findings In this quality improvement study analysis of 33 primary care practices including 19 254 patients eligible for breast cancer screening and 33 468 patients eligible for colorectal cancer screening, both clinician ordering and patient completion of c...

FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need
https://www.cytodyn.com/media/press-releases/detail/328/fda-grants-cytodyn-fast-track-designation-for-leronlimab

May 6th, 2019 - CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation to leronlimab (PRO140) for use in combination with carboplatin for the treatment of patients...

FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
https://www.gene.com/media/press-releases/14785/2019-05-03/fda-approves-genentechs-kadcyla-for-adju

May 2nd, 2019 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla® (ado-trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin® (trastuzumab)-based treatment.

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease
https://www.esmo.org/Guidelines/Gynaecological-Cancers/ESMO-ESGO-Consensus-Conference-Recommendations-on-Ovarian-Cancer

May 1st, 2019 - The ESMO–ESGO consensus conference manuscript on ovarian cancer was developed by a multidisciplinary panel of 40 leading experts and presents evidence-based recommendations in several areas in an effort to improve the quality of care for women with ovarian cancer. The recommendations focus on pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurre...

Antioxidant; Camellia sinensis; Free radical; Green tea; Matcha
http://www.cqaimh.org/pdf/tool_phq9.pdf

Apr 18th, 2019 - The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring and measuring the severity of depression.

Screening for Elevated Blood Lead Levels in Children and Pregnant Women: US Preventive ... Preview
https://doi.org/10.1001/jama.2019.3326
JAMA , Curry SJ et. al.

Apr 16th, 2019 - Elevated blood lead levels in children are associated with neurologic effects such as behavioral and learning problems, lower IQ, hyperactivity, hearing problems, and impaired growth. In pregnant women, lead exposure can impair organ systems such as the hematopoietic, hepatic, renal, and nervous systems, and increase the risk of preeclampsia and adverse perinatal outcomes. Many of the adverse h...